Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
NCT01674010 · OPKO Health, Inc. · PHASE2 · terminated · last registry update 2019-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business Decision” | – | Registry record, OPKO Health, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-16Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02477670)
- 2020-07-09Phase 3 first posted: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT04464564)
- 2020-05-29Phase 3 first posted: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT04408755)
- 2020-01-14Phase 3 first posted: Pancreatic Cancer Action Network, Gemcitabine combined with nab-paclitaxel + Dose -mFOLFIRINOX (NCT04229004)
- 2019-11-29Results posted on the registry: New York State Psychiatric Institute, Placebo + Intranasal Oxytocin (NCT02255357)
- 2019-07-30Phase 3 first posted: University of Pennsylvania, Anti Arrhythmics (NCT04037397)
- 2019-04-01Phase 3 first posted: Otsuka Pharmaceutical Development & Commercialization, Inc., Placebo + AVP-786 (NCT03896945)
- 2019-02-26Phase 3 first posted: The University of Texas Health Science Center, Houston, Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) + Placebo (NCT03854019)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision